Mastering Core Pharmacology for the ABFM Exam

Success on the American Board of Family Medicine (ABFM) certification exam requires a high-level mastery of therapeutic guidelines and the physiological rationale behind drug selection. Candidates must navigate an expansive list of ABFM pharmacology must-know medications, focusing not just on drug names, but on clinical decision-making, side effect profiles, and long-term monitoring. The exam emphasizes the application of evidence-based medicine to diverse patient populations, often presenting scenarios where comorbidities dictate specific pharmacological choices. This review bridges the gap between basic pharmacology and clinical practice, providing the depth needed to identify the most appropriate agent for a given clinical vignette while avoiding common prescribing pitfalls. Understanding the nuances of drug-drug interactions, dose adjustments for renal impairment, and the specific monitoring requirements for high-risk medications is essential for achieving a passing score and ensuring patient safety in family medicine practice.

ABFM Pharmacology Must-Know Medications: Antibiotic Stewardship

First-Line Antibiotics for Common Outpatient Infections

Selecting the correct antibiotic requires a precise understanding of the most likely pathogens and local resistance patterns. For acute otitis media in the pediatric population, high-dose amoxicillin (80–90 mg/kg/day) remains the gold standard, targeting Streptococcus pneumoniae. In adult respiratory health, the antibiotic selection guidelines family medicine practitioners must recall include the use of doxycycline or macrolides for uncomplicated community-acquired pneumonia (CAP) in healthy outpatients, whereas those with comorbidities require a respiratory fluoroquinolone or a combination of a beta-lactam plus a macrolide. For uncomplicated urinary tract infections (UTIs) in women, nitrofurantoin is the preferred first-line agent due to its high urinary concentration and minimal systemic absorption, provided the creatinine clearance is above 30 mL/min. Trimethoprim-sulfamethoxazole is an alternative, though its utility is limited if local E. coli resistance exceeds 20%. Skin and soft tissue infections suspected to be non-purulent cellulitis are typically treated with cephalexin to cover beta-hemolytic streptococci, while purulent cases necessitate coverage for Methicillin-resistant Staphylococcus aureus (MRSA) with clindamycin or doxycycline.

Managing Penicillin and Other Drug Allergies

Distinguishing between a true IgE-mediated type I hypersensitivity reaction and a non-allergic intolerance is a critical skill for the ABFM. A history of anaphylaxis, angioedema, or urticaria shortly after penicillin administration precludes the use of most beta-lactams. However, the cross-reactivity rate between penicillins and third- or fourth-generation cephalosporins is lower than previously thought, often cited at less than 1%. If the reaction was a non-urticarial rash, a cephalosporin can often be used safely. In cases of severe penicillin allergy, macrolides or clindamycin serve as alternatives for pharyngitis. For surgical prophylaxis, vancomycin or clindamycin may replace cefazolin. Candidates must also recognize the risks associated with sulfa allergies, particularly the potential for cross-reactivity with certain diuretics or sulfonylureas, although this is clinically rare. Documentation of the specific reaction type is a cornerstone of antibiotic stewardship, preventing the unnecessary use of broad-spectrum agents that drive resistance.

Duration of Therapy and When to Reassess

Modern guidelines increasingly favor shorter courses of antimicrobial therapy to minimize the selection of resistant organisms and reduce adverse effects like Clostridioides difficile infection. For uncomplicated CAP, a 5-day course is often sufficient if the patient is clinically stable and afebrile. Similarly, uncomplicated UTIs treated with trimethoprim-sulfamethoxazole require only 3 days, whereas nitrofurantoin requires 5 days. The ABFM exam may test the "watchful waiting" approach for acute otitis media or rhinosinusitis, where antibiotics are deferred for 48–72 hours in non-severe cases. Reassessment is vital; if a patient fails to improve within 72 hours, clinicians must reconsider the diagnosis or the spectrum of coverage. This involves evaluating for complications, such as abscess formation or the presence of a resistant pathogen not covered by the initial empiric choice. The goal is to transition from empiric to targeted therapy as soon as culture results or clinical milestones allow.

Diabetes and Endocrine Pharmacotherapy

Metformin, SGLT2 Inhibitors, and GLP-1 Agonists: Mechanisms and Benefits

Metformin remains the first-line pharmacotherapy for Type 2 Diabetes Mellitus (T2DM) due to its efficacy, safety, and low cost. Its primary diabetes medications mechanism of action involves the activation of AMP-activated protein kinase (AMPK), which leads to decreased hepatic gluconeogenesis and improved peripheral insulin sensitivity. Sodium-glucose cotransporter 2 (SGLT2) inhibitors, such as empagliflozin, work in the proximal tubule of the kidney to induce glucosuria, thereby lowering blood glucose and providing significant cardiovascular and renal protection. These agents are particularly beneficial for patients with heart failure or chronic kidney disease (CKD). Glucagon-like peptide-1 (GLP-1) receptor agonists, like liraglutide, mimic the incretin effect, enhancing glucose-dependent insulin secretion, slowing gastric emptying, and promoting satiety. The ABFM emphasizes the use of SGLT2 inhibitors and GLP-1 agonists in patients with established atherosclerotic cardiovascular disease (ASCVD), regardless of their baseline HbA1c, due to their proven mortality benefits.

Insulin Types, Dosing, and Hypoglycemia Management

When oral and non-insulin injectable agents fail to reach the glycemic target, insulin initiation becomes necessary. Basal insulins, such as glargine or detemir, provide a steady state of insulin for 24 hours with no pronounced peak, mimicking physiologic basal secretion. Rapid-acting insulins (lispro, aspart) are used for prandial coverage. The exam may require calculating a total daily dose (TDD), typically starting at 0.1–0.2 units/kg for basal insulin. A critical aspect of management is the "Rule of 15" for treating hypoglycemia: consuming 15 grams of rapid-acting carbohydrates and rechecking blood glucose in 15 minutes. For patients on insulin, the risk of nocturnal hypoglycemia must be balanced against the goal of achieving an HbA1c typically below 7.0%, though targets are often relaxed to <8.0% in older adults with multiple comorbidities to prevent falls and cognitive impairment associated with low blood sugar levels.

Thyroid Disorder Medications: Levothyroxine and Antithyroid Drugs

Levothyroxine is the treatment of choice for hypothyroidism, with a standard replacement dose of approximately 1.6 mcg/kg/day in healthy young adults. However, in elderly patients or those with known coronary artery disease, the adage "start low and go slow" applies, often beginning at 12.5–25 mcg daily to avoid precipitating angina or arrhythmias. TSH levels should be checked 6–8 weeks after any dose adjustment. For hyperthyroidism, methimazole is generally preferred over propylthiouracil (PTU) due to a lower risk of hepatotoxicity, except during the first trimester of pregnancy when PTU is favored to avoid methimazole-associated embryopathy. Candidates must be aware of the rare but serious side effect of agranulocytosis; patients should be instructed to report a sudden sore throat or fever immediately. Monitoring for thyroid storm or myxedema coma represents the extreme ends of thyroid pathology that may appear in acute care scenarios on the exam.

Cardiovascular Medications: From Hypertension to Heart Failure

First-Line Antihypertensives and Compelling Indications

According to the JNC 8 and subsequent ACC/AHA guidelines, first-line agents for hypertension include thiazide-type diuretics, Calcium Channel Blockers (CCBs), and ACE inhibitors or Angiotensin Receptor Blockers (ARBs). The choice is often driven by "compelling indications." For instance, patients with T2DM and albuminuria (uACR ≥ 30 mg/g) should be started on an ACE inhibitor or ARB to provide renal protection. Patients of African descent without CKD often respond better to thiazides or CCBs as initial therapy. Common side effects are high-yield: ACE inhibitors can cause a dry cough due to bradykinin accumulation, while dihydropyridine CCBs like amlodipine frequently cause peripheral edema. Beta-blockers are no longer considered first-line for uncomplicated hypertension but are essential for patients with a history of myocardial infarction or stable ischemic heart disease to reduce myocardial oxygen demand and prevent remodeling.

Statin Therapy Intensity and Monitoring

Statin therapy is categorized into high, moderate, and low intensity based on the expected percentage reduction in LDL-C. High-intensity statins (atorvastatin 40–80 mg or rosuvastatin 20–40 mg) are indicated for patients with established ASCVD or those with an LDL-C ≥ 190 mg/dL. For primary prevention in patients aged 40–75 with diabetes, at least moderate-intensity statin therapy is required. The ABFM focuses on the Pooled Cohort Equations to calculate the 10-year ASCVD risk; a risk ≥ 7.5% often triggers a discussion about starting a statin. Routine monitoring of liver enzymes (ALT) is no longer recommended unless the patient is symptomatic. However, monitoring for statin-associated muscle symptoms (SAMS) is crucial. If a patient develops significant myalgia, the statin should be held, and a creatine kinase (CK) level should be checked to rule out rhabdomyolysis before attempting a trial of a different statin or a lower dose.

Guideline-Directed Medical Therapy for Heart Failure

Management of Heart Failure with reduced Ejection Fraction (HFrEF) centers on Guideline-Directed Medical Therapy (GDMT), which has been shown to reduce mortality and hospitalizations. The "four pillars" of GDMT include an ARNI (sacubitril/valsartan), a beta-blocker (specifically carvedilol, metoprolol succinate, or bisoprolol), a Mineralocorticoid Receptor Antagonist (MRA) like spironolactone, and an SGLT2 inhibitor. When transitioning a patient from an ACE inhibitor to an ARNI, a 36-hour washout period is mandatory to prevent angioedema. Diuretics, while essential for symptom management and maintaining euvolemia, do not confer a survival benefit. Candidates should be familiar with the NYHA Functional Classification, as it guides the escalation of therapy. Monitoring electrolytes and renal function is paramount when using ACE/ARBs, ARNIs, and MRAs, as hyperkalemia and rising creatinine can limit the ability to up-titrate these life-saving medications.

Psychotropic Drugs: Antidepressants, Antipsychotics, and Mood Stabilizers

SSRI/SNRI Selection and Side Effect Profiles

Selective Serotonin Reuptake Inhibitors (SSRIs) are the first-line treatment for major depressive disorder and various anxiety disorders. The choice among them is often based on the psychotropic drugs side effects monitoring requirements and the patient's specific symptoms. For example, fluoxetine has a long half-life, making it a good choice for patients who occasionally miss doses, whereas paroxetine is more sedating and associated with higher rates of weight gain and sexual dysfunction. Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) like venlafaxine or duloxetine are useful when depression is accompanied by chronic pain, though venlafaxine can cause dose-dependent increases in blood pressure. All SSRIs/SNRIs carry a black box warning regarding increased suicidal ideation in children and young adults. Clinicians must also watch for the Serotonin Syndrome—characterized by autonomic instability, hyperreflexia, and mental status changes—especially when these agents are combined with other serotonergic drugs like tramadol or triptans.

Metabolic Monitoring for Atypical Antipsychotics

Second-generation (atypical) antipsychotics (SGAs), such as quetiapine, risperidone, and olanzapine, are used for schizophrenia, bipolar disorder, and as adjunctive therapy in resistant depression. While they have a lower risk of extrapyramidal symptoms (EPS) compared to first-generation agents, they are heavily associated with metabolic syndrome. The ABFM requires knowledge of the specific monitoring protocol: baseline and periodic measurement of weight (BMI), waist circumference, blood pressure, fasting plasma glucose, and a lipid profile. Olanzapine and clozapine carry the highest risk for weight gain and dyslipidemia. Clozapine also requires rigorous monitoring of the Absolute Neutrophil Count (ANC) due to the risk of life-threatening agranulocytosis. If a patient develops signs of tardive dyskinesia—involuntary movements of the face or tongue—the SGA should be tapered and potentially switched to an agent with a lower EPS profile like quetiapine.

Lithium and Anticonvulsant Mood Stabilizers: Levels and Toxicity

Lithium remains a primary treatment for bipolar disorder, but it has a narrow therapeutic index, typically requiring serum levels between 0.6 and 1.2 mEq/L. Toxicity can be precipitated by dehydration, NSAIDs, ACE inhibitors, or thiazide diuretics, all of which increase lithium levels. Symptoms of toxicity include coarse tremors, ataxia, vomiting, and confusion. Long-term lithium use requires monitoring of renal function and thyroid-stimulating hormone (TSH), as it can cause nephrogenic diabetes insipidus and hypothyroidism. Anticonvulsants like valproic acid and carbamazepine are also used as mood stabilizers. Valproic acid requires monitoring of liver function tests and a CBC (for thrombocytopenia), and it is highly teratogenic (neural tube defects). Carbamazepine is a potent inducer of the cytochrome P450 system, leading to numerous drug interactions, and requires screening for the HLA-B*1502 allele in certain populations to prevent Stevens-Johnson Syndrome.

Anticoagulation and Antiplatelet Therapy

DOACs vs Warfarin: Dosing, Monitoring, and Reversal

Direct Oral Anticoagulants (DOACs), including apixaban and rivaroxaban (Factor Xa inhibitors) and dabigatran (direct thrombin inhibitor), are now preferred over warfarin for non-valvular atrial fibrillation and venous thromboembolism (VTE). DOACs do not require routine INR monitoring and have a lower risk of intracranial hemorrhage. However, dosing must be adjusted for renal function, and they are contraindicated in patients with mechanical heart valves. Warfarin remains the standard for valvular AF and antiphospholipid syndrome. For anticoagulation reversal agents, the ABFM expects knowledge of specific antidotes: idarucizumab for dabigatran and andexanet alfa for Factor Xa inhibitors. For warfarin, reversal is achieved using Vitamin K (oral or IV) and 4-factor Prothrombin Complex Concentrate (PCC) or Fresh Frozen Plasma (FFP) in cases of life-threatening bleeding. The choice of agent depends on the urgency of the situation and the specific drug the patient is taking.

Aspirin and P2Y12 Inhibitors in Primary and Secondary Prevention

Aspirin is no longer routinely recommended for the primary prevention of ASCVD in adults over 60, as the bleeding risk often outweighs the cardiovascular benefit. In secondary prevention, however, aspirin (81 mg) is a cornerstone of therapy. Following an Acute Coronary Syndrome (ACS) or percutaneous coronary intervention (PCI), Dual Antiplatelet Therapy (DAPT) with aspirin and a P2Y12 inhibitor (clopidogrel, ticagrelor, or prasugrel) is required, typically for 6 to 12 months. Ticagrelor is often preferred over clopidogrel in ACS due to more consistent platelet inhibition, but it can cause transient dyspnea. Clopidogrel is a prodrug that requires activation by the CYP2C19 enzyme; patients who are poor metabolizers may have reduced efficacy. When prescribing DAPT, clinicians must assess the patient's bleeding risk (e.g., using the HAS-BLED score) and consider the addition of a proton pump inhibitor for gastroprotection in those at high risk for GI bleeding.

Perioperative Management of Anticoagulation

Managing anticoagulants before surgery requires a balance between the risk of thromboembolism and the risk of surgical bleeding. For minor procedures (e.g., dental work, cataract surgery), anticoagulation can often be continued. For major surgeries, DOACs are typically held for 24–72 hours depending on the drug's half-life and the patient's renal function. "Bridging" with low-molecular-weight heparin (LMWH) is generally reserved for warfarin-treated patients with a very high thromboembolic risk, such as those with a mechanical mitral valve or a recent (within 3 months) VTE. For most patients with atrial fibrillation and a moderate CHADS2-VASc score, bridging is not necessary and may actually increase the risk of bleeding without reducing the risk of stroke. Postoperatively, anticoagulation should be resumed as soon as hemostasis is achieved, usually within 24–72 hours.

Pain Management and Controlled Substances

NSAIDs, Acetaminophen, and Topical Analgesics

Non-opioid analgesics are the first-line recommendation for most chronic non-cancer pain. Acetaminophen is effective for mild-to-moderate pain, but the total daily dose should not exceed 3–4 grams to avoid hepatotoxicity. Non-steroidal anti-inflammatory drugs (NSAIDs) are highly effective for inflammatory pain but carry significant risks of GI bleeding, renal impairment, and cardiovascular events. Naproxen is often considered the "safest" NSAID from a cardiovascular standpoint. Topical NSAIDs, such as diclofenac gel, are preferred for localized osteoarthritis (e.g., the knee) as they provide similar efficacy to oral versions with much lower systemic absorption and fewer side effects. For neuropathic pain, topical lidocaine or capsaicin patches can be used as adjuncts. The goal is to maximize non-pharmacological and non-opioid treatments before considering more potent systemic agents.

Opioid Prescribing: Risk Assessment, Agreements, and Monitoring

When opioids are necessary for chronic pain, they should be prescribed at the lowest effective dose for the shortest possible duration. Before initiating therapy, clinicians must perform a risk assessment using tools like the Opioid Risk Tool (ORT) and check the state's Prescription Drug Monitoring Program (PDMP). A formal "pain agreement" or "controlled substance contract" should be signed, outlining the patient's responsibilities, including random urine drug screening (UDS). UDS is used to ensure compliance and detect the use of non-prescribed substances. Clinicians should be familiar with Morphine Milligram Equivalents (MME); doses exceeding 50 MME/day should trigger a reassessment, and doses ≥ 90 MME/day are generally discouraged. Co-prescribing naloxone is recommended for patients at high risk of overdose, including those on high doses or those also taking benzodiazepines, which significantly increases the risk of respiratory depression.

Medications for Neuropathic Pain and Migraine Prophylaxis

Neuropathic pain, such as diabetic peripheral neuropathy or postherpetic neuralgia, responds poorly to traditional analgesics. First-line agents include gabapentinoids (gabapentin, pregabalin), TCAs (amitriptyline, nortriptyline), and SNRIs (duloxetine). Gabapentin requires upward titration and can cause sedation and peripheral edema. For migraine management, acute treatment involves triptans (e.g., sumatriptan), which are 5-HT1B/1D agonists; they are contraindicated in patients with CAD or uncontrolled hypertension due to vasoconstrictive effects. Preventive therapy is indicated if migraines occur ≥ 4 days per month or are significantly disabling. Options for prophylaxis include beta-blockers (propranolol), anticonvulsants (topiramate, valproate), and TCAs. Topiramate is often favored for patients desiring weight loss but can cause "brain fog" and nephrolithiasis. CGRP antagonists represent a newer class for both acute and preventive treatment but are usually reserved for patients who fail traditional therapies.

Medication Safety, Deprescribing, and Immunizations

Applying the Beers Criteria in Geriatric Patients

Medication safety and deprescribing are central themes in geriatric family medicine. The Beers Criteria, maintained by the American Geriatrics Society, lists medications that should generally be avoided in adults aged 65 and older. High-yield examples include diphenhydramine (anticholinergic effects leading to confusion and falls), long-acting benzodiazepines (increased risk of hip fractures), and sliding-scale insulin (increased risk of hypoglycemia without benefit). Deprescribing is the proactive process of tapering or stopping medications where the harm outweighs the benefit. This is particularly important for PPIs (risk of fractures and C. diff), antipsychotics used for behavioral symptoms of dementia, and statins in patients with a limited life expectancy. Systematic reviews of the medication list at every visit help reduce polypharmacy and the "prescribing cascade," where a new drug is prescribed to treat the side effect of an existing one.

Recognizing High-Risk Drug-Drug Interactions

Pharmacokinetic and pharmacodynamic interactions can lead to treatment failure or toxicity. One of the most critical areas is the CYP450 system. For example, clarithromycin is a potent inhibitor of CYP3A4; if given to a patient on simvastatin, it can lead to toxic levels of the statin and rhabdomyolysis. Another high-yield interaction involves warfarin and antibiotics; most broad-spectrum antibiotics (especially TMP-SMX and metronidazole) can increase the INR by altering gut flora or inhibiting warfarin metabolism. NSAIDs should be avoided in patients on anticoagulants or those with heart failure, as they can cause fluid retention and increase bleeding risk. The combination of an ACE inhibitor, a diuretic, and an NSAID—often called the "triple whammy"—is a frequent cause of acute kidney injury in the outpatient setting. Recognizing these combinations is essential for safe prescribing and is a frequent focus of ABFM questions.

Adult Immunization Schedules and Special Populations

The ABFM exam tests the current CDC adult immunization schedule. Key vaccines include the annual influenza vaccine and the Tdap (tetanus, diphtheria, and acellular pertussis) booster given once, followed by Td or Tdap every 10 years. For pneumococcal vaccination, the current standard for adults ≥ 65 (or younger with certain risks) is either a single dose of PCV20 or a dose of PCV15 followed by PPSV23. The recombinant zoster vaccine (Shingrix) is recommended for all adults ≥ 50, regardless of prior shingles infection. In special populations, such as pregnant women, the Tdap vaccine should be administered during each pregnancy (ideally between 27–36 weeks) to provide passive immunity to the neonate. Live vaccines, such as MMR and varicella, are contraindicated in pregnancy and severely immunocompromised individuals. Staying current with vaccination updates ensures both board success and the delivery of high-quality preventive care.